Alcobra Company Profile (NASDAQ:ADHD)

Analyst Ratings

Consensus Ratings for Alcobra (NASDAQ:ADHD) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $11.80 (177.65% upside)

Analysts' Ratings History for Alcobra (NASDAQ:ADHD)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016Roth CapitalReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Canaccord GenuityInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Cantor FitzgeraldInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/18/2016Jefferies GroupInitiated CoverageBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/25/2016Oppenheimer Holdings Inc.Initiated CoverageOutperform$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/9/2015WBB SecuritiesReiterated RatingHold$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Piper Jaffray Cos.Set Price TargetBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2014FBR & CoDowngradeOutperform -> Market Perform$22.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014ING GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Alcobra (NASDAQ:ADHD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
7/27/2016N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/16/2016Q116($0.22)($0.18)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2016Q415($0.24)($0.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2015Q315($0.31)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.30)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015($0.31)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q4($0.57)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2014Q3 14($0.56)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q2($0.57)($0.57)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014Q114($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014Q413($0.35)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q213($0.06)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alcobra (NASDAQ:ADHD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.19)($0.15)($0.17)
Q2 20163($0.22)($0.20)($0.21)
Q3 20163($0.27)($0.22)($0.25)
Q4 20163($0.40)($0.28)($0.32)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.18)($0.18)($0.18)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alcobra (NASDAQ:ADHD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alcobra (NASDAQ:ADHD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Alcobra (NASDAQ:ADHD)
DateHeadline
07/26/16 02:21 PMCan Shares Of Alcobra Ltd. (NASDAQ:ADHD) Hit $17? - Investor Newswire
07/23/16 02:18 PMStock Displaying Signs of a Downtrend: Alcobra Ltd. (NASDAQ:ADHD) - Press Telegraph
07/22/16 02:17 PMWere Analysts Bullish Alcobra Ltd (NASDAQ:ADHD) This Week? - Consumer Eagle
07/19/16 07:45 PMAlcobra Granted European Orphan Drug Designation for Metadoxine in Fragile X Syndrome
07/19/16 02:18 PMChina Metro-Rural Holdings Limited (NYSEMKT:CNR) plummeted -15.07% : Alcobra Ltd. (NASDAQ:ADHD ... - KC Register
07/19/16 08:30 AMIs $17 Price Target Attainable For Alcobra Ltd. (NASDAQ:ADHD)? - Investor Newswire
07/19/16 08:30 AMAlcobra Ltd. (ADHD) Granted EC Orphan Drug Designation for Metadoxine in Fragile X Syndrome - StreetInsider.com
07/16/16 02:19 PMAlcobra Limited Ord (NASDAQ:ADHD) Shorts Decreased by 3.56% After Short Covering - Consumer Eagle
07/15/16 06:35 PMNew Broker Ratings For Alcobra Ltd. (ADHD) - FTSE News
07/12/16 08:20 AMStrong Sell Calls For Alcobra Ltd. (NASDAQ:ADHD) At 0 - Investor Newswire
07/10/16 02:18 PMAlcobra Limited Ord (NASDAQ:ADHD) Short Interest Decreased By 3.56% - Engelwood Daily
07/10/16 07:03 AMNext Weeks Broker Price Targets For Alcobra Ltd. (ADHD) - Fiscal Standard
07/08/16 02:20 PMInvestors Watch List: Alcobra Ltd. (NASDAQ:ADHD), KeyCorp. (NYSE:KEY), Symantec Corporation (NASDAQ:SYMC ... - KC Register
07/07/16 02:19 PMHow Many Alcobra Ltd (NASDAQ:ADHD)'s Analysts Are Bullish? - Press Telegraph
07/06/16 02:19 PMBroker Outlook For Alcobra Ltd. (ADHD) - Fiscal Standard
07/05/16 02:18 PMAlcobra Ltd. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - GlobeNewswire (press release)
07/05/16 07:00 AMAlcobra Ltd. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - [GlobeNewswire] - TEL AVIV, Israel, July 05, 2016-- Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit ...
07/04/16 07:05 AMBroker Outlook For The Week Ahead Alcobra Ltd. (ADHD) - Fiscal Standard
06/29/16 02:16 PMAlcobra Limited Ord (NASDAQ:ADHD) Shorted Shares Decreased By 3.56% - Engelwood Daily
06/28/16 07:30 AMRoth Capital Reinstates Alcobra Ltd to Buy - Trade Calls
06/28/16 07:30 AMStrong Sell Calls Recommendations For Alcobra Ltd. (NASDAQ:ADHD) At 0 - Investor Newswire
06/27/16 07:04 AMAlcobra Ltd. (ADHD) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 02:16 PMAlcobra Ltd. (ADHD) Updated Price Targets - FTSE News
06/23/16 10:04 AMAlcobra Ltd. (NasdaqGM:ADHD) Stock Momentum Hits Weakness - CML News
06/21/16 07:05 AMStrong Buy Calls Count For Alcobra Ltd. (NASDAQ:ADHD) At 4 - Investor Newswire
06/08/16 08:24 PMAnalysts Offer Insights on Healthcare Companies: Alcobra Ltd (NASDAQ: ADHD), Atara Biotherapeutics Inc (NASDAQ ... - Analyst Ratings
06/07/16 10:42 AMAlcobra Shares Initiated At Buy; Cantor Sees 'Greater Opportunity For Success'
06/07/16 08:41 AMCoverage initiated on Alcobra Pharma by Cantor Fitzgerald -
06/06/16 01:31 PMAlcobra Ltd. :ADHD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/05/16 10:11 AMNext Weeks Broker Price Targets For Alcobra Ltd. (ADHD) - Share Trading News
06/03/16 02:20 PMBuy, Sell Or Hold Rating For Alcobra Ltd. (ADHD)? - Share Trading News
06/01/16 10:42 AMAlcobra Ltd. to Participate in Upcoming Investment Conferences - GlobeNewswire (press release) - Alcobra Ltd. to Participate in Upcoming Investment ConferencesGlobeNewswire (press release)TEL AVIV, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity ...Alcobra Ltd. (ADHD) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsAlcobra Limited Ord (NASDAQ:ADHD) Shorted Shares Increased By 5.92%HNNall 3 news articles »
06/01/16 07:23 AMAlcobra Ltd. to Participate in Upcoming Investment Conferences - [at noodls] - TEL AVIV, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, ...
05/25/16 05:43 PMWere Analysts Bearish Alcobra Ltd (NASDAQ:ADHD) This Week? - Wall Street Hints and News - Were Analysts Bearish Alcobra Ltd (NASDAQ:ADHD) This Week?Wall Street Hints and NewsOut of 6 analysts covering Alcobra (NASDAQ:ADHD), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Alcobra has been the topic of 6 analyst reports since August 9, 2015 according to StockzIntelligence Inc. Below is a list of ...and more »
05/22/16 10:26 AMRevenue Update on Alcobra Ltd(NASDAQ:ADHD) - Trade Calls - Revenue Update on Alcobra Ltd(NASDAQ:ADHD)Trade CallsAlcobra Ltd(NASDAQ:ADHD) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 16, 2016. Earnings per share were $-0.18. Analysts had estimated an EPS of $-0.22. In a different note, Jefferies said it ...
05/20/16 09:25 AMAlcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session - Nasdaq - Alcobra (ADHD) Catches Eye: Stock Adds 6.3% in SessionNasdaqAlcobra LtdADHD was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company since ...and more »
05/20/16 07:30 AMAlcobra (ADHD) Catches Eye: Stock Adds 6.3% in Session -
05/20/16 05:08 AM7 Stocks Under $10 Making Big Moves Higher -
05/17/16 05:36 PMAlcobra (ADHD) Gains With Losses on Horizon - Alcobra Ltd (NASDAQ: ADHD) shares advanced 3.7% to $4.18. The company is projected to post a quarterly loss at $0.22 per share. Share volume was 22,000, compared to an all-day average of 27,000
05/16/16 05:30 PMAfter Last Week What Do Analysts Think Of Alcobra Ltd. (ADHD) - Share Trading News - After Last Week What Do Analysts Think Of Alcobra Ltd. (ADHD)Share Trading News12/04/2013 – Stifel Nicolaus began new coverage on Alcobra Ltd. giving the company a “buy” rating. They now have a USD 27 price target on the stock. The share price of Alcobra Ltd. (ADHD) was up +9.81% during the last trading session, with a day high ...Alcobra Announces First Quarter 2016 Financial Results and Provides Corporate UpdateGlobeNewswire (press release)Alcobra's (ADHD) CEO Yaron Daniely on Q1 2016 Results - Earnings Call TranscriptSeeking Alphaall 6 news articles »
05/16/16 09:49 AMEdited Transcript of ADHD earnings conference call or presentation 16-May-16 12:30pm GMT -
05/16/16 08:30 AMThe Zacks Analyst Blog Highlights: Alcobra, Editas Medicine, Syndax Pharmaceuticals, Seres Therapeutics and Neos Therapeutics -
05/16/16 07:32 AMAlcobra Announces First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - Conference Call & Webcast May 16th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time TEL AVIV, Israel, May 16, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused ...
05/16/16 07:15 AMAlcobra reports 1Q loss -
05/16/16 07:03 AM8:03 am Alcobra Pharma reports Q1 results; MEASURE study data expected by year end -
05/16/16 06:07 AMQ1 2016 Alcobra Ltd Earnings Release - Before Market Open -
05/12/16 06:08 PMLatest Analyst Ratings For Alcobra Ltd. (ADHD) - Share Trading News - Latest Analyst Ratings For Alcobra Ltd. (ADHD)Share Trading News02/04/2016 – Alcobra Ltd. had its “buy” rating reiterated by analysts at Roth Capital. 01/25/2016 – Oppenheimer began new coverage on Alcobra Ltd. giving the company a “outperform” rating. They now have a USD 16 price target on the stock. 06/24/2015 ...and more »
05/09/16 04:28 AMAlcobra Limited Ord (NASDAQ:ADHD) Shorted Shares Decreased By 6.4% - B.O.D.Y Confidential - Alcobra Limited Ord (NASDAQ:ADHD) Shorted Shares Decreased By 6.4%B.O.D.Y ConfidentialThe stock of Alcobra Limited Ord (NASDAQ:ADHD) registered a decrease of 6.4% in short interest. ADHD's total short interest was 1.87 million shares in May as published by FINRA. Its down 6.4% from 2.00 million shares, reported previously. With 160,800 ...and more »
05/08/16 06:16 PMBroker Outlook For The Week Ahead Alcobra Ltd. (ADHD) - Share Trading News - Broker Outlook For The Week Ahead Alcobra Ltd. (ADHD)Share Trading NewsAlcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in ...and more »
05/04/16 06:00 PMBroker Roundup For Alcobra Ltd. (ADHD) - Share Trading News - Broker Roundup For Alcobra Ltd. (ADHD)Share Trading News12/04/2013 – Stifel Nicolaus began new coverage on Alcobra Ltd. giving the company a “buy” rating. They now have a USD 27 price target on the stock. The share price of Alcobra Ltd. (ADHD) was up +2.95% during the last trading session, with a day high ...Alcobra Ltd.: Alcobra Ltd. to Release First Quarter Financial Results and Host Corporate Update Conference Call ...The Wall Street Transcriptall 2 news articles »

Social

About Alcobra

Alcobra logoAlcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADHD
  • CUSIP:
Key Metrics:
  • Previous Close: $4.25
  • 50 Day Moving Average: $4.53
  • 200 Day Moving Average: $4.60
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $117.14M
  • Beta: 1.31
  • Current Year EPS Consensus Estimate: $-0.98 EPS
  • Next Year EPS Consensus Estimate: $-1.03 EPS
Additional Links:
Alcobra (NASDAQ:ADHD) Chart for Wednesday, July, 27, 2016